Skip to main content
NVDA-0.16%AAPL+1.12%GOOGL-2.28%MSFT+0.01%AMZN+0.01%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.79%TSLA-0.52%SKHY+7.05%MU-1.36%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.46%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.59%0005.HK-0.78%HSBA.L-1.72%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.28%CHFJPY-1.76%USDJPY-1.65%AUDJPY-1.59%EURJPY-1.48%CADJPY-1.48%GBPJPY-1.43%GBPNZD+0.85%EURNZD+0.83%NZDCAD-0.82%AUDNZD+0.72%NZDUSD-0.65%NZDCHF-0.55%GBPTRY+0.41%GBPHKD+0.32%GBPCHF+0.32%GBPMXN-0.28%EURCHF+0.27%CADCHF+0.27%USDNOK+0.26%EURNOK+0.26%GBPUSD+0.22%CHFNOK+0.20%NOKJPY-0.18%AUDCHF+0.18%EURZAR+0.17%USDZAR+0.17%EURUSD+0.16%GBPZAR+0.16%USDCAD-0.16%USDILS+0.16%NZDSGD+0.16%AUDCAD-0.14%AUDDKK-0.14%GBPAUD+0.14%USDTHB+0.13%AUDNOK+0.12%USDCHF+0.12%EURAUD+0.11%USDTRY+0.11%NZDMXN+0.11%EURCZK-0.09%USDSGD+0.08%EURSGD+0.08%USDSEK+0.07%EURSEK+0.07%USDPLN+0.06%AUDSGD-0.06%AUDUSD+0.06%GBPSGD+0.06%EURPLN+0.06%USDMXN+0.05%USDCOP-0.04%EURGBP-0.03%GBPCAD+0.03%USDCNH-0.03%PLNJPY+0.02%EURHKD-0.01%USDHKD+0.01%EURCNH-0.01%CHFSGD+0.01%CHFSEK+0.01%EURCAD-0.01%USDDKK0.00%EURDKK0.00%SGDJPY0.00%COFFEE-2.34%SUGAR+1.74%XPTUSD-1.64%COTTON+1.27%XAGUSD-0.97%GAGUSD-0.97%COCOA-0.85%USOIL+0.60%S1+0.56%C1+0.52%HG1-0.49%UKOIL+0.43%BTCUSD-0.41%ETHUSD+0.04%USDTUSD-0.04%XRPUSD-1.28%SOLUSD-0.47%TRXUSDT+0.39%ZECUSDT-1.92%DOGEUSD-1.47%XMRUSDT-0.80%LINKUSD-0.12%XLMUSD-1.05%BCHUSDT-1.77%LTCUSD-1.62%UNIUSD-2.08%TONUSD+24.88%HBARUSDT-1.34%SUIUSD-1.35%TAOUSDT-0.91%AAVEUSD-1.54%DOTUSDT-2.45%ICPUSDT-1.19%ONDOUSDT-1.98%WLDUSDT-1.95%ATOMUSDT-2.11%ARBUSDT-0.67%JUPUSDT-2.96%INJUSDT-2.83%STXUSDT-2.70%FETUSDT-2.21%TIAUSDT-0.87%SEIUSDT-3.91%PYTHUSDT-1.22%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-2.03%OPUSDT-1.99%POLUSDT-3.05%IOTAUSDT-2.34%AXSUSDT-1.93%FARTCOINUSDT-1.60%EOSUSDT-0.19%DYDXUSDT-0.40%ORDIUSDT+0.61%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%NVDA-0.16%AAPL+1.12%GOOGL-2.28%MSFT+0.01%AMZN+0.01%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.79%TSLA-0.52%SKHY+7.05%MU-1.36%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.46%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.59%0005.HK-0.78%HSBA.L-1.72%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.28%CHFJPY-1.76%USDJPY-1.65%AUDJPY-1.59%EURJPY-1.48%CADJPY-1.48%GBPJPY-1.43%GBPNZD+0.85%EURNZD+0.83%NZDCAD-0.82%AUDNZD+0.72%NZDUSD-0.65%NZDCHF-0.55%GBPTRY+0.41%GBPHKD+0.32%GBPCHF+0.32%GBPMXN-0.28%EURCHF+0.27%CADCHF+0.27%USDNOK+0.26%EURNOK+0.26%GBPUSD+0.22%CHFNOK+0.20%NOKJPY-0.18%AUDCHF+0.18%EURZAR+0.17%USDZAR+0.17%EURUSD+0.16%GBPZAR+0.16%USDCAD-0.16%USDILS+0.16%NZDSGD+0.16%AUDCAD-0.14%AUDDKK-0.14%GBPAUD+0.14%USDTHB+0.13%AUDNOK+0.12%USDCHF+0.12%EURAUD+0.11%USDTRY+0.11%NZDMXN+0.11%EURCZK-0.09%USDSGD+0.08%EURSGD+0.08%USDSEK+0.07%EURSEK+0.07%USDPLN+0.06%AUDSGD-0.06%AUDUSD+0.06%GBPSGD+0.06%EURPLN+0.06%USDMXN+0.05%USDCOP-0.04%EURGBP-0.03%GBPCAD+0.03%USDCNH-0.03%PLNJPY+0.02%EURHKD-0.01%USDHKD+0.01%EURCNH-0.01%CHFSGD+0.01%CHFSEK+0.01%EURCAD-0.01%USDDKK0.00%EURDKK0.00%SGDJPY0.00%COFFEE-2.34%SUGAR+1.74%XPTUSD-1.64%COTTON+1.27%XAGUSD-0.97%GAGUSD-0.97%COCOA-0.85%USOIL+0.60%S1+0.56%C1+0.52%HG1-0.49%UKOIL+0.43%BTCUSD-0.41%ETHUSD+0.04%USDTUSD-0.04%XRPUSD-1.28%SOLUSD-0.47%TRXUSDT+0.39%ZECUSDT-1.92%DOGEUSD-1.47%XMRUSDT-0.80%LINKUSD-0.12%XLMUSD-1.05%BCHUSDT-1.77%LTCUSD-1.62%UNIUSD-2.08%TONUSD+24.88%HBARUSDT-1.34%SUIUSD-1.35%TAOUSDT-0.91%AAVEUSD-1.54%DOTUSDT-2.45%ICPUSDT-1.19%ONDOUSDT-1.98%WLDUSDT-1.95%ATOMUSDT-2.11%ARBUSDT-0.67%JUPUSDT-2.96%INJUSDT-2.83%STXUSDT-2.70%FETUSDT-2.21%TIAUSDT-0.87%SEIUSDT-3.91%PYTHUSDT-1.22%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-2.03%OPUSDT-1.99%POLUSDT-3.05%IOTAUSDT-2.34%AXSUSDT-1.93%FARTCOINUSDT-1.60%EOSUSDT-0.19%DYDXUSDT-0.40%ORDIUSDT+0.61%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%
LP

Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ • Healthcare

$288.05
-$0.77 (-0.3%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$287.88
Day Range$285.28 - $291.68
Avg. Volume (3M)200.6K
Market Cap$5.7B
P/E Ratio28.8
52 Week Range
$161.82$326.63
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$63.6M100%
Gross Profitminus cost of goods$60.4M95%
Operating Incomeminus R&D and overhead$8.5M13%
Net Incomeminus taxes and the rest$48.5M76%

In plain terms: out of every $100 in revenue, Ligand Pharmaceuticals Incorporated keeps $76 as net profit.

Fundamentals & Financials

Revenue (TTM)
$290.5M
Net Income (TTM)
$197.2M
EPS (TTM)
$10.01
ROA (TTM)
9.02%
Current Ratio
31.18
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+38.4%Q1 2026$2.02
-11.4%Q2 2026$1.63
+17.9%Q3 2026$2.37
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +17.9%

Ligand Pharmaceuticals topped consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, as revenue of $63.7 million topped the $61.3 million estimate, +3.9%, while adjusted EPS of $2.37 topped the $2.01 estimate, +17.9%. Revenue rose ~34% year over year to roughly $63.7 million from about $47.6 million a year ago, alongside GAAP operating income of about $8.6 million as operating margin stood near 14%. GAAP net income surged roughly 901% year over year to about $48.5 million, up from roughly $4.8 million a year ago. The quarter generated operating cash flow of roughly $24.0 million, and the company repurchased about $60.0 million of stock. Next-period consensus calls for EPS of $2.30 on revenue of $78.1 million.

View full earnings history

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biotechnology company that licenses and supports a portfolio of marketed medicines and formulation technology for pharmaceutical companies worldwide. Its business spans oncology, vaccines, central nervous system, anti-infective, cardiovascular, and bone-health products, and generated $268.1 million of revenue in FY2025.

Name
Ligand Pharmaceuticals Incorporated
CEO
Todd C. Davis
Website
www.ligand.com
Industry
Healthcare
Year Founded
1987
Employees
47

Today's Snapshot

AI-generated

LGND ended the day slightly lower at 288.05, in line with a flat sector. Trading was busier than usual, with volume about half as much again as its usual level.

Trading Volume

Above 10d avg 190.6K

306.6K

vs S&P 500 Today

Moderate Outperformance

+0.15%

Updated: September 9, 2026 at 20:15 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
LGND shows constructive price behavior with the market sitting above key short- and medium-term moving averages and comfortably above the long-term 200-day average, while on‑balance volume is positive, supporting the advance. Momentum indicators are mixed but tilted slightly positive, and MACD is neutral, indicating room for consolidation rather than a decisive reversal. Volatility is contained and the ADX is low, implying the trend lacks strong force even as price structure remains favorable. Technical takeaway: Buy — moving averages and volume support a bullish stance.
All signals
  • EMA (5 indicators)$241.17 - $287.90
    Buy
  • RSI (14)49.59
    Neutral
  • Stochastic %K (14, 3, 3)64.09
    Neutral
  • MACD Level (12, 26)-1.42
    Neutral

Peers & Related Assets

PRAXPraxis Precision Medicines, Inc.
$345.3-2.0%
CRNXCrinetics Pharmaceuticals, Inc.
$84.950.0%
MIRMMirum Pharmaceuticals, Inc.
$98.3-1.2%
ACADACADIA Pharmaceuticals Inc.
$27.68+0.4%
VKTXViking Therapeutics, Inc.
$32.7-2.9%
DYNDyne Therapeutics, Inc.
$19.19-5.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.